Want to see CLVT full AI Analyst Report?
Top Page
Clarivate
(NYSE:CLVT)
Select Model
Select Model
Rating:53Neutral
Price Target:
$1.50
▼(-26.11% Downside)
Action:Reiterated
Date:10/07/26
The score is held up by solid cash generation and improving operating performance/margin outlook discussed on the earnings call, alongside manageable (and improving) leverage. It is weighed down by persistent net losses and ongoing revenue decline, and further pressured by weak price trends and negative momentum across key technical indicators.
Positive Factors
Focused portfolio and debt reduction
The divestiture sharpens Clarivate’s focus on Academia & Government and Intellectual Property while directing proceeds toward debt reduction. A more focused portfolio and lower leverage can improve financial flexibility, support investment in core platforms, and strengthen the subscription-led model.
Negative Factors
Persistent revenue contraction
Shrinking reported and organic revenue indicates that Clarivate’s recurring growth is not yet sufficient to offset transactional weakness and portfolio disposals. Continued top-line pressure can limit operating leverage, reduce investment capacity, and make the broader recovery dependent on successful execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused portfolio and debt reduction
The divestiture sharpens Clarivate’s focus on Academia & Government and Intellectual Property while directing proceeds toward debt reduction. A more focused portfolio and lower leverage can improve financial flexibility, support investment in core platforms, and strengthen the subscription-led model.
Read all positive factors
Clarivate (CLVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.03B
Dividend YieldN/A
Average Volume (3M)4.04M
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth-3.50%
EPS Growth16.13%
CountryUS
Employees12,000
SectorTechnology
Sector Strength88
IndustryInformation Technology Services
Share Statistics
EPS (TTM)-0.52
Shares Outstanding639,664,000
10 Day Avg. Volume3,615,330
30 Day Avg. Volume4,040,041
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.46
Price to Sales (P/S)0.92
P/FCF Ratio6.16
Enterprise Value/Market Cap5.26
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit3.36
Enterprise Value/Ebitda8.14
Forecast
1Y Price Target
$3.02Price Target Upside48.77% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)0.74
Revenue Forecast (FY)$2.31B
Clarivate Business Overview & Revenue Model
Company Description
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scien...
How the Company Makes Money
Clarivate primarily makes money by selling subscription access to its proprietary datasets, analytics, and workflow software, complemented by services tied to implementation and advisory work. (1) Subscription revenue: A significant portion of rev...
Clarivate Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Positive
The call emphasized clear progress on strategic priorities—AI product launches with early commercial traction, margin expansion, debt reduction and a higher-quality recurring revenue mix driven by portfolio rationalization. These positives were tempered by near-term headwinds including a large non-cash impairment related to the LS&H divestiture, transactional revenue declines, one-time transaction costs that depress free cash flow this year, and FX impacts. Management presented a credible path to sequential organic growth and profitability improvement in the second half, with stronger recurring revenue mix and disciplined capital allocation supporting confidence in longer-term execution.Positive Updates
Organic ACV and Recurring Revenue Momentum
Organic ACV improved to 1.5% in Q2; Academia & Government and Life Sciences & Healthcare each delivered ~2% organic ACV growth. Recurring organic revenue growth is ~1.5% near the midpoint of guidance and management expects sequential improvement in the second half with A&G approaching 3% and IP returning to growth by year-end.
Negative Updates
Q2 Net Loss Driven by Non-Cash Impairment
Net loss in Q2 was $269 million, driven entirely by a non-cash impairment charge triggered by the definitive agreement to divest the LS&H segment.
Read all updates
Q2-2026 Updates
Positive
Negative
Organic ACV and Recurring Revenue Momentum
Organic ACV improved to 1.5% in Q2; Academia & Government and Life Sciences & Healthcare each delivered ~2% organic ACV growth. Recurring organic revenue growth is ~1.5% near the midpoint of guidance and management expects sequential improvement in the second half with A&G approaching 3% and IP returning to growth by year-end.
Read all positive updates
Company Guidance
Management reaffirmed full‑year guidance but refined its outlook to reflect the planned LS&H divestiture: organic ACV is expected in the lower half of the range with recurring organic growth about 1.5% at the midpoint (A&G approaching ~3% and IP returning to growth by year‑end to blend to ~2.25%); full‑year revenue is now expected just below midpoint at $2.35 billion, adjusted EBITDA just over $1.0 billion (implying ~43% margin and ~200 bps of margin expansion year‑over‑year), adjusted diluted EPS about $0.75 (≈9% growth), and free cash flow at the low end of the range largely due to nearly $70 million of one‑time divestiture costs — yet management still expects to reduce debt by roughly $900 million this year; other guideposts include a pro forma recurring revenue mix of ~92%, $25 million of cost‑efficiency driven profit improvement, inorganic disposals lowering revenue by about $125 million while cutting operating expense by ~$100 million, a ~$20 million improvement in cash interest, $5–10 million higher cash taxes, a ~$25 million working‑capital use, a $10 million benefit from lower impaired contractual costs, and about $20 million lower capex.Clarivate Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
52
Neutral
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.41B | 2.46B | 2.56B | 2.63B | 2.66B | 1.88B |
| Gross Profit | 1.61B | 1.62B | 1.69B | 1.72B | 1.71B | 1.25B |
| EBITDA | 666.10M | 929.30M | 456.60M | -10.50M | -3.01B | 532.15M |
| Net Income | -334.00M | -201.10M | -636.70M | -911.20M | -3.96B | -270.50M |
Balance Sheet | ||||||
| Total Assets | 10.49B | 11.07B | 11.49B | 12.71B | 13.94B | 20.18B |
| Cash, Cash Equivalents and Short-Term Investments | 217.70M | 329.20M | 295.20M | 370.70M | 348.80M | 587.61M |
| Total Debt | 4.26B | 4.48B | 4.59B | 4.81B | 5.07B | 5.61B |
| Total Liabilities | 5.95B | 6.23B | 6.35B | 6.71B | 7.13B | 8.26B |
| Stockholders Equity | 4.54B | 4.84B | 5.14B | 5.99B | 6.81B | 11.93B |
Cash Flow | ||||||
| Free Cash Flow | 327.60M | 365.30M | 357.50M | 501.70M | 306.40M | 205.30M |
| Operating Cash Flow | 574.40M | 628.50M | 646.60M | 744.20M | 509.30M | 323.80M |
| Investing Cash Flow | -246.80M | -263.20M | -236.70M | -237.40M | 57.30M | -4.04B |
| Financing Cash Flow | -463.80M | -343.10M | -470.10M | -496.50M | -759.20M | 4.03B |
Clarivate Technical Analysis
Negative
2.03
Price Trends
1.87
Negative
2.07
Negative
2.34
Negative
Market Momentum
-0.11
Positive
39.81
Neutral
60.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLVT, the sentiment is Negative. The current price of 2.03 is above the 20-day moving average (MA) of 1.71, above the 50-day MA of 1.87, and below the 200-day MA of 2.34, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 39.81 is Neutral, neither overbought nor oversold. The STOCH value of 60.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLVT.
Clarivate Risk Analysis
Clarivate disclosed 44 risk factors in its most recent earnings report. Clarivate reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clarivate Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $131.49B | 15.73 | 26.77% | 3.07% | 6.47% | 11.19% | |
77 Outperform | $5.77B | 10.10 | 22.91% | 2.13% | 6.89% | 11.22% | |
76 Outperform | $5.57B | 23.11 | 28.49% | ― | 13.63% | 9.52% | |
68 Neutral | $12.26B | 17.39 | 401.44% | ― | 0.68% | -31.71% | |
65 Neutral | $213.88B | 19.83 | 33.52% | 2.97% | 7.90% | 82.11% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
53 Neutral | $1.03B | -3.09 | -7.00% | ― | -3.50% | 16.13% |
* Technology Sector Average
CLVT
Clarivate
1.61
-1.99
-55.28%
ACN
Accenture
214.87
-23.01
-9.67%
EXLS
Exlservice Holdings
36.74
-4.27
-10.41%
IT
Gartner
194.10
-52.63
-21.33%
G
Genpact
34.35
-4.73
-12.10%
IBM
International Business Machines
227.02
-42.13
-15.65%
Clarivate Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Clarivate Divests Life Sciences Unit to Refocus Core
Positive
Oct 6, 2026
On October 6, 2026, Clarivate completed the $600 million sale of its Life Sciences Healthcare segment to Altaris, LLC, receiving $500 million in cash at closing, a $75 million unsecured senior note and an additional $25 million in deferred consid...
Business Operations and StrategyPrivate Placements and Financing
Clarivate Completes Partial Tender Offer for 2028 Notes
Neutral
Sep 24, 2026
On September 24, 2026, Clarivate announced the final results of a cash tender offer conducted by its subsidiary Clarivate Science Holdings Corporation for its 3.875% Senior Secured Notes due 2028. The offer, capped at a $75 million maximum princip...
Business Operations and StrategyPrivate Placements and Financing
Clarivate Launches Tender Offer for 2028 Secured Notes
Neutral
Sep 23, 2026
On September 23, 2026, Clarivate Plc announced the pricing terms for a cash tender offer by its subsidiary Clarivate Science Holdings Corporation to purchase a portion of its 3.875% Senior Secured Notes due 2028. The offer, capped at $75 million o...
Business Operations and StrategyPrivate Placements and Financing
Clarivate Launches Tender Offer to Manage Secured Debt
Positive
Sep 17, 2026
On September 17, 2026, Clarivate announced that its wholly owned subsidiary, Clarivate Science Holdings Corporation, launched a cash tender offer for its 3.875% Senior Secured Notes due July 1, 2028, with $825 million outstanding. The offer is cap...
Business Operations and StrategyExecutive/Board Changes
Clarivate Appoints New CFO and Chief Accounting Officer
Positive
Jul 29, 2026
On July 24, 2026 Clarivate announced that Executive Vice President and Chief Financial Officer Jonathan Collins had resigned, effective August 7, 2026, to pursue another opportunity, with the company specifying that his departure was not due to an...
Business Operations and StrategyFinancial Disclosures
Clarivate Reports Mixed Second-Quarter 2026 Financial Results
Negative
Jul 29, 2026
On July 29, 2026, Clarivate reported second-quarter 2026 results showing total revenue of $587.3 million, down 5.5% year-on-year, mainly due to divestitures and disposals, with a 1.5% decline in organic revenue as subscription growth was offset by...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.